GLP-1 drugs have become the hottest drug class in a generation, driven by an obesity epidemic affecting 40% of American adults and linked to diabetes, heart disease and a growing list of other conditions. But there’s a catch: up to two-thirds of adults report some level of needle fear. A 2022 PLOS One international survey…
GLP-1 agonist supply shortages and access inequities frustrate patients and doctors
GLP-1 agonists may have turned obesity treatment upside down, becoming a viral phenomenon thanks to social media acclaim and celebrity endorsements along with their ability to support tangible weight loss results for many patients. But the skyrocketing demand for these therapies has a shadow side, leading to supply shortages, access inequities and bureaucratic hurdles that…
GLP-1s, ADCs, AI and the future of pharma
Pharma’s potential breakthroughs in AI, ADCs, and GLP-1 receptor agonists raise a critical question: can innovation outpace the relentless rise of chronic disease? The IQVIA Institute for Human Data Science sheds light on this theme, among many others, in its 80-page Global Trends in R&D 2024 report. Pillar 1: GLP-1 receptor agonists targeting metabolic disease…